Introduction
Hedgehog (Hh) is a developmental signaling pathway that regulates embryonic cell growth, body pattern formation and organogenesis in certain vertebrate tissues. Hh signaling leads to increased activity of Gli transcriptional factors and increased transcription of Gli target genes (1) , and its signaling pathway driven by Hh ligands regulates the genes that are involved in cell proliferation, differentiation and cell motility (2) . Although it is involved in the epithelial and stromal compartments during normal prostate development and in regulating growth, maturation and maintenance of the differentiated state in the adult (3), there is increasing evidence that dysregulated Hh signaling plays some role in prostate cancer (PCa) (4) . Also, stromal fibroblasts respond to and actively react with stimuli from cancer epithelium (5) .
On the other hand, androgen regulates the expression of several key molecules in the Hh signaling pathway including members of the Gli transcription factor family.
The potential relationship between androgen and the expression of some critical molecules in the Hh signaling pathway might explain some of the aberrations in Hh signaling reported to occur in PCa. Androgen depletion strongly upregulates expression of Hh ligands and Gli targets, and markedly elevates sonic hedgehog (Shh) expression in human PCa cells (1) . This indicates the potential for chronic androgen deprivation therapy to create a Hh signaling environment for primary or metastatic prostate tumors that might improve the response of these tumors to therapy on a long-term basis (4) . Therapeutically targeting Hh signaling in human primary and/or bone metastatic PCa could therefore prove to be beneficial (6) .
Recently, osteonectin (ON) was identified in interaction between normal human prostate stromal cells and PCa; moreover, recombinant Shh protein was identified as not only a new Shh-Gli1 target gene but possible Shh target gene in our previous work (7) . In addition, epithelial-mesenchymal transition (EMT) is known to promote cancer progression via loss of cell adhesion, repression of E-cadherin expression and increased cell mobility; there are several oncogenic pathways that induce EMT (8) .
In this study, we investigated how Shh signaling and representative androgen, dihydrotestosterone (DHT) works in prostate epithelial and stromal compartments and drive EMT in PCa progression, using cell proliferation assays and real time reverse transcription polymerase chain reaction (RT-PCR). We used immunohistochemical (IHC) analyses to explore the significant markers for aggressive clinical PCa, including high serum prostate specific antigen (PSA) and high Gleason scores (GSs), especially focusing on potential epithelial or stromal Shh signaling target genes, ON expression, and biochemical recurrence in PCa patients. and DHT added together at the same concentration. In addition, in order to evaluate the effect of stromal cells CM on PCa cell proliferation, CM from NPF and CM from CPF were added to LNCaP and cell proliferation was assayed after 48 hours treatments. CM was prepared according to a previous study (9) . All experiments were carried out in triplicate. Data were expressed as mean ± standard deviation (S.D.) and evaluated for statistical significance.
Cell proliferation assay

RT-PCR
Total RNA was isolated from confluent monolayers of cells using TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA), followed the manufacturer's instructions. Table I . These primers were designed in our laboratory.
IHC study
IHC staining of radical prostatectomy (RP) specimens of 25 patients from the Department of Urology, Akashi Municipal Hospital, was performed as previously 
Results
LNCaP cell proliferation after treatment with cyclopamine
Hh signaling inhibitor, Cy (5, 10, and 20 µM) inhibited LNCaP cell proliferation in 96 hours treatments and revealed its inhibition in a dose-dependent manner especially in 144 hours treatments (Fig. 1) .
Comparison of LNCaP, NPF and CPF responses to DHT and cyclopamine
We compared the responses of LNCaP cell lines and NPF or CPF to DHT and DHT + Cy in order to investigate how the prostate tumor and stromal compartments react to DHT and Cy. First, the results showed that DHT tended to enhance cell proliferation in CPF x 1.71 times (significant difference from control; p<0.0001) (Fig.   2C ) more than in LNCaP (x 1.14) (significant difference from control; p=0.0001) ( Fig. 2A) or NPF (x 1.13) (significant difference from control; p>0.05 (Fig. 2B) .
Next, the addition of Cy to DHT showed significantly inhibited effects in LNCaP (x 0.917; p=0.0059) and CPF (x 0.788; p=0.0006), but not NPF (x 0.912; p=0.0887).
These data suggested that CPF have potentially more reaction to DHT with the addition of Cy than LNCaP or NPF, indicating that Cy could have more of an effect on cancer associated stromal cells but not necessarily from cancer cells nor normal/benign prostate stromal cells. (Fig. 2) .
The comparison of LNCaP cell proliferation in the presence of NPF CM and CPF
CM
We compared the LNCaP cell proliferation assay with CM from NPF and CPF.
LNCaP cells in the presence of CM from grew faster than those with CM from NPF (p=0.0017) (Fig 3) .
Shh and cyclopamine effects on EMT in LNCap
Recombinant However, the effects of Cy or DHT+Cy were indicated in ON, N-cadherin and Vimentin (in Cy, p=0.0084, p=0.0002 and p=0.0373, respectively) (in DHT+Cy, p=0.0002, p=0.0007 and p=0.0085, respectively) ( Fig. 4B and 4C ).
IHC staining results
Representative findings from IHC staining of PCa specimens for expression of ON, (Fig. 5) .
Relationship between IHC analyses and patients' clinical and pathological data
Statistical analyses of clinical data and IHC results (Table II) showed that ONstr had a significant correlation with serum PSA (p=0.031). Importantly, PCa recurrence had a significant correlation with Gli-1 (p=0.0114) and low expression of ONstr (p=0.0005), suggesting that the expression of ONstr may correlate to PCa initiation as shown in our previous work (9) . The significant correlation was not found between clinicopathological data and EMT marker (E-cadherin, N-cadherin and Vimentin). Also, the significant correlation between serum PSA and IHC stainings was not found in both normal and cancer tissue (Table III) . As to cytoplasmic AR stainings, we did not find that cytoplasmic staining was specific to AR in all Gleason grades (p=0.1489).
Discussion
The Hh signaling pathway has an axial function in the development and patterning of many endodermally derived tissues, and evidence from several studies suggests that Hh pathway activity in PCa promotes tumor growth, invasion, metastasis, and hormone independence (7) . In recent PCa chemotherapy, targeting the Hh pathway has shown promising results, and Smoothened (Smo) and Glis have been considered primary targets for anti-Hh therapeutics (14) . A corn lily steroidal alkaloid, Cy, inhibits intracellular Hh signaling by blocking the activity of Smo. Efforts to develop and apply anti-Hh therapeutics have been ongoing for several years (15) .
In this study, CPF reacted to androgens (DHT) more than LNCaP or NPF and to
Cy in the presence of DHT more than LNCaP or NPF, and also our CM study showed CM from CPF significantly affected LNCapP cell proliferation more than NPF. These results suggest, taken together with our previous study (16) , that CPF may be a reactive stroma especially in the presence of androgens (DHT) and may have different proliferative signaling from NPF in this condition. Our findings in CPF may offer a hint for understanding androgen-dependent PCa (LNCaP) cell heterogeneity and the evolution from androgen-dependent to independent PCa. These in vitro results, taken together with our previous studies (5) This should also be explored with a greater number of patient samples to further understand the relationship between Hh signaling and EMT markers in PCa progression.
In conclusion, Shh signaling plays a role in PCa through a relationship with androgens and drives EMT in the tumor and stromal compartments. DHT-induced ON expression or reactive prostate stroma (cancer-associated stroma) may be a possible target in PCa progression especially in androgen independent status and Hh signaling inhibitor Cy might be a potential therapeutic strategy for PCa. 
Figure legends
